Proposed US COINS Act Rules for China Biotech Deals, Global Relay Intelligence & Practice
12 novembre 2026Morgan Lewis partners Todd Liao, David Plotinsky, and Carl Valenstein co-authored an article for Global Relay Intelligence & Practice examining how proposed US outbound investment restrictions under the Comprehensive Outbound Investment National Security Act of 2025 (COINS Act) could affect cross-border biotechnology transactions involving China.
The authors explain that while standalone drug licensing agreements would generally fall outside the proposed restrictions, related equity investments, financing arrangements, joint ventures, and new company structures could be prohibited depending on their ownership, governance, and economic arrangements. They also address potential implications for US investors in foreign funds and overlapping Chinese technology export requirements.
Read the full Global Relay Intelligence & Practice article >>
Subscription required.